作者: Kevin L. Billups , Laura Berman , Jennifer Berman , Michael E. Metz , Margaret E. Glennon
DOI: 10.1080/713846826
关键词:
摘要: Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment the first FDA cleared-to-market therapy for FSD. Clitoral engorgement believed to play an important role in female sexual arousal and overall satisfaction. a small, battery-powered device designed enhance clitoral engorgement, increase blood flow clitoris, ultimately improve women with objective this study was assess effectiveness on (genital sensation, vaginal lubrication, ability reach orgasm, satisfaction) normal volunteers